The company was founded in December 2019 by a team which originated from the Institute of Molecular Biology and Biotechnology at the Foundation for Research and Technology – Hellas (IMBB-FORTH).
In August 2020, BIOPIX-T received funding from a covid response call from the European program H2020 (IRIS-COV), within a consortium of 8 partners, in order to productize, certify and release into the market its portable molecular diagnostic device for the point of care, based on a prototype named IRIS. The resulting product was Pebble.
In September 2020, BIOPIX-T also secured its seed funding round with lead investor the Greek venture capital Metavallon and three angel investors from the Greek healthcare market. Later-on that year it concluded the round with the addition of the venture capital Eleven from Bulgaria.
The current product range of BIOPIX-T consists of the Pebble for diagnostic use at the point of care and its associated test kits for the detection of Sars-CoV2 and Flu A (soon), as well as a research use version of the Pebble, which is addressed to the academic and research community.
The founding team consists of professionals all of which have a strong scientific background and a deep understanding of the molecular diagnostic device market while most of them are actively involved in the management and development of the company.
Apart from the founders, BIOPIX-T is supported by a rapidly growing team of outstanding professionals with high expertise in our respective fields and a great appetite for innovation, covering all aspects of the business from R&D and bringing further innovative solutions for the point of care and home testing to the market.
We love finding solutions, crafting new ideas and we know there is no better way ahead than collaboration. Our mission is simple: we are eager to conquer the molecular diagnostics space and are very serious about it.